Emily M. Leproust (Chief Executive Officer) sold ~$8.64M of Twist Bioscience
Automatic saleTWST · NASDAQ · Biological Products, (No Diagnostic Substances)
Biological Products, (No Diagnostic Substances) company based in South San Francisco, Ca.
In the last 90 days, no insider of Twist Bioscience reported an open-market purchase and 20 open-market sales worth about $20.4M. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 6, 2026
$166.97
Last 12 months
Not enough history
Market value
Not available
Bets against the stock: 12.5M shares sold short, +3.6% vs the previous count, 8.9 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Revenue
$118M
+23.2% vs the same quarter a year earlier
Free cash flow, last 12 months
−$93.1M
This quarter −$8.65M, a year earlier −$10.6M
Net debt
—
Debt —, cash $117M, at Jun 30, 2026
Backlog
$21.9M
Work contracted but not yet delivered, as the company reports it
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 3, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
20 sales
$20.4M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Dennis Cho (See Remarks) sold ~$1.8M of Twist Bioscience
Automatic salePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Fails to deliver: 27K shares (about $3.33M) were not delivered on time for settlement on Aug 18, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.